Sign In

News Story

CohnReznick invests $100k in ACS research project

​Our aim is to better understand the impact housing discrimination has on cancer risk.

We’re excited to share that CohnReznik – the advisory, assurance, and tax firm where John Alfonso, chair of the American Cancer Society Board of Directors, serves as partner and leader of the firm’s not-for-profit and education industry practice – has invested $100,000 to support a new ACS research project focused on better understanding the impact of housing discrimination on cancer risk.  

CohnReznick is the first corporate partner to support this research project, and John was instrumental in securing the gift. Thank you to John, CohnReznick CEO David Kessler, and the entire CohnReznick team for their leadership in getting this important project started! CohnReznick will also engage with the affordable housing development community to drive collaboration and support for this initiative.

The study, called the Systemic and Biologic Impact of Housing Discrimination on Cancer Risk project, will help us better understand how racism contributes to cancer disparities. It’ll examine how aspects of neighborhood environments, such as walkability, availability of fresh fruits and vegetables, air pollution, and more, drive expected associations between housing discrimination and cancer. Using entirely new and groundbreaking science, we also seek to prove that individuals who live in these areas have cancer-related biologic changes to the DNA as a result of where they live.  

This work will also help inform new and lasting strategies to reduce racism’s impact on cancer risk and survival, while increasing our understanding about how to improve access to quality care.

The four-year project will be led by Alpa Patel, PhD, SVP, population science, and is expected to launch in 2022. The project will leverage data and blood sample collected from CPS-3’s 300,000 study participants. 

We are seeking an additional $5 million in donor funds to support direct costs, laboratory assays, implementation, and other costs associated with conducting the study. 

back to top